# Reward Sensitivity and Pharmacotherapy for Smoking Cessation

> **NCT02162849** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 204 (actual)

## Conditions studied

- Tobacco Use Cessation

## Interventions

- **DRUG:** Varenicline
- **DRUG:** Nicotine Patch
- **DRUG:** Placebo Patch
- **DRUG:** Placebo Tablet
- **BEHAVIORAL:** Questionnaires
- **BEHAVIORAL:** Counseling Sessions
- **OTHER:** Lab Session
- **OTHER:** Saliva Test

## Key facts

- **NCT ID:** NCT02162849
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-14
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- NAL PHARMA
- Pfizer

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02162849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02162849, "Reward Sensitivity and Pharmacotherapy for Smoking Cessation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02162849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*